about
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantSequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Acute Lymphoblastic LeukemiaOfatumumab for Minimal Residual Disease (MRD) and Maintenance TherapyCellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic LeukemiaPhase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmSafety Study of Dinutuximab Combined With Immunotherapy to Treat NeuroblastomaEffect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplantsAssessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune RepertoireComparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationAzacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual DiseaseAn Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseFractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid LeukemiaCapecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative ChemotherapyHMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCTDaratumumab in Treating Transplant-Eligible Participants With Multiple MyelomaDaratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell TransplantPembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseStem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid LeukemiaCD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic LeukemiaExpanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid LeukemiaMonitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic SyndromeThe Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AMLNon-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUSCD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell TransplantationFeasibility of the LUM Imaging System for Detection of Prostate CancerIntraoperative Detection of Residual Cancer in Breast CancerAutologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer PatientsRuxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsRivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantPevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCapecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative ChemotherapySafety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple MyelomaPivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer PatientsA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell TransplantPembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic LeukemiaStudy of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
P1050
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cellsDeep Response in Multiple Myeloma: A Critical ReviewCurrent treatment options for local residual nasopharyngeal carcinomaMonitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesMinimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisSignificance of lobular intraepithelial neoplasia at margins of breast conservation specimens: a report of 38 cases and literature review.Advanced therapeutic strategy for radiation-induced osteosarcoma in the skull base: a case report and reviewPositive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequences.Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistanceMinimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual DiseaseComparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer
P921
Q58407709-614CDC09-EEF3-4449-8934-E4D5C11E920EQ58407893-31AA2795-5FC0-43F6-BAF1-21CB9398322BQ58844706-C41715D9-9EC7-410B-8E92-0E960D523921Q58845022-C4D25F6C-CDE6-43D2-B0A0-261B5FE339F5Q58845041-D5761F8B-6FB8-4411-ACEC-B08913766AAFQ58849620-9ED63D9E-9FA3-4294-8DAA-DF0FFBC425CFQ58849632-2808B252-1B1A-45A4-A5D5-3E0877CCE6B5Q61902283-58DBDAEA-124F-4D70-9E94-B997D609DFC0Q61904985-2172E5BB-F0D8-4B49-9373-26132086FCBFQ61907523-234ED230-1A6A-48B4-B563-46093E44BBE8Q61965699-F066B92A-07FD-44C1-9F29-2AF6C7FC14B5Q61981243-8778F54C-7410-4989-ADBC-40A248CCEF0FQ62031403-00AC9715-03E6-40DA-81AC-5C2B5B2638FBQ62035353-C184283C-C660-4C08-B7FF-28C32E8D3259Q62054624-E300F3EB-594A-42EC-8180-9E232FA125EEQ62062257-D8D78B86-2D74-4E8E-AB2D-6E618301B566Q62812962-F69877BF-5A32-43D6-B493-5939A6EB0E6DQ62813512-3855BA36-C13A-41F7-841B-55B254E1A9F7Q62817877-4C49D375-3550-4C5F-8F00-6822970512DEQ62818125-05E3D855-5AFD-484B-8E1A-CFC5E101594DQ63011831-6247B617-6067-4693-A0DA-46EFE13B8321Q63229127-79367561-9423-454D-B71F-33D4C58890EFQ63335596-E9BF5329-9943-48CB-9B90-B72CE5146C44Q63339183-3BDE5591-075C-435B-B312-8E8556D6E51DQ63393573-536629E2-98F4-4A4B-BDE4-DF83C6D14352Q63397348-26AADCDB-A84C-4BC0-A978-D41FEA05D21DQ63398733-A3652D5E-6D88-4AE3-B9B7-48982389874AQ63400961-AB41BDF5-75F8-4DDF-B697-21F05BA5196EQ63534796-F7F78719-8FB1-4EBB-A057-5B2F4D19F0FDQ63571240-6AE5BE5D-FB58-45C3-9579-C062BAD23CA0Q63571601-3F847AA7-8F85-46FA-9B06-B806C64A0B3AQ63584379-0A6C525D-71B0-4431-9202-E6243384A49AQ63595824-45E3323D-E745-425C-82F4-27AEBD189E1AQ63596434-4B641E8C-2EE5-48F2-966E-5E718FC47FEAQ63597380-E22E3AE8-F426-42E6-B58E-5C2AB97439E1Q63597947-41081745-8741-41C3-8909-0CE53FA1FAC1Q63599800-8FF75409-8B6E-4580-AAA3-334866483E5DQ63805814-21F67961-26E5-457C-9250-B8EBCECA9DAFQ63807851-23B167F6-1C33-49F9-89AA-9FB7926984BFQ63807923-238F134B-F8C2-4149-B28C-03ADB00508BD
P1050
Q26748850-B2E98F21-A2C6-4B34-ACA9-ACAF2B9D8535Q26771228-D50D5840-ADBB-4796-9520-15D35CF3E365Q26852207-24E7AB14-7E89-4B84-B009-1AF66B05E88CQ28076096-08ACF465-F248-4939-B934-419C305F4620Q33815986-A2F13F14-BF52-44C9-85E1-CA6CCF1BA98EQ34114482-6ED202DC-19E8-448E-A5C9-C0E6851B4333Q36621341-F6A0428F-0888-45A3-8231-1295B11444F5Q38237943-6D5864F1-B56F-4804-A595-7E595B365E96Q38249332-7BDE3045-81C1-4D5C-91B2-26E3FD5519EEQ55291531-A0896AA1-9EDF-47ED-93AF-E56100746A5DQ60920843-C56F5507-718D-4962-886F-9D6AF4F3BAF9Q61808955-6B63AC08-E82C-4681-BD74-66E79C2655A1
P921
description
A neoplasm listed in Medical Subject Headings (MeSH)
@en
name
neoplasm, residual
@en
type
label
neoplasm, residual
@en
prefLabel
neoplasm, residual
@en
P486
P1995
P279
P31
P486
P672
C04.697.700
C23.550.727.700